Frovocimab
From EverybodyWiki Bios & Wiki
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | PCSK9 |
| Clinical data | |
| Synonyms | LY3015014 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}} |
| Chemical and physical data | |
| Formula | C6506H10062N1718O2036S46 |
| Molar mass | 146.4 g/mol g·mol−1 |
Frovocimab (LY3015014) (INN) is a monoclonal antibody designed for the treatment of hypercholesterolemia.[1][2]
This drug is being developed by Eli Lilly and Company.
References[edit]
 | This monoclonal antibody–related article is a stub. You can help EverybodyWiki by expanding it. |
This article "Frovocimab" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Frovocimab. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
